Financial Data and Key Metrics Changes - Total revenue for the second quarter of 2025 was $7.7 million, down 9% compared to 2024, primarily due to challenges in the international environment [20] - Global recurring revenue was $5.1 million, a decline of 4% year-over-year [20] - Gross profit for the quarter was $4.3 million, representing 56% of revenue, down from $5 million in the same period of 2024 [21] - Total operating expenses increased to $6.5 million, up roughly $1 million from the prior year [22] - Adjusted EBITDA for the second quarter was a loss of $762,000 [23] Business Line Data and Key Metrics Changes - XTRAC gross domestic recurring billings were $4.7 million, a decline of 2% compared to the prior year [20] - Equipment revenue was $2.5 million, down 18% versus 2024, affected by international market challenges [20] - The installed base of TheraClear X devices reached 161 units, up from 117 at the end of 2024 [11] Market Data and Key Metrics Changes - International revenue was $2.6 million, a decline of 15% compared to the prior year, impacted by trade disruptions in China and distributor challenges in Korea [12] - The domestic market has approximately 18 million patients with atopic dermatitis, indicating a significant potential market for the company's products [19] Company Strategy and Development Direction - The company is focused on expanding its addressable market to 30 million patients by leveraging newly expanded CPT codes for various skin conditions [6] - The Elevate360 consulting model aims to improve revenue for clinics and the company by optimizing the use of XTRAC lasers [7] - The company is pursuing litigation against LaserOptik for false advertising, which could result in significant damages [14][33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth opportunities due to expanded reimbursement eligibility and the potential tripling of the patient population [26] - There is caution regarding the impact of tariffs on international business, particularly in China [26] - The company anticipates a stronger second half of 2025, although uncertainties remain due to tariffs [28][30] Other Important Information - The company has submitted economic data to support potential increases in reimbursement rates for its codes [6] - Recent peer-reviewed studies support the efficacy of excimer laser therapy, expanding its potential applications [17][18] - The company is actively engaging with CMS and the AMA to secure temporary G codes for expanded indications [54][61] Q&A Session Summary Question: Expectations for the international business in the second half of the year - Management expects the second half to be similar to the prior year but cautioned that tariffs could significantly impact results [28][30] Question: Details on the lawsuit and expected damages - The expected damages from the lawsuit against LaserOptik are in the eight-digit range, with legal expenses mostly behind the company [32][33][39] Question: Metrics on Elevate360 consulting services impact - Clinics that completed the Elevate360 process showed higher revenue in Q2 compared to the previous year, with some experiencing significant growth [62] Question: Status of TheraClear devices and revenue growth - The focus remains on XTRAC devices due to their higher revenue potential, while TheraClear revenue is growing but remains small [70]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $6.8 million, up 1% compared to Q1 2024 [16] - Global recurring revenue for Q1 2025 was $4.7 million, also up 1% year-over-year [16] - Gross profit increased to $3.6 million for Q1 2025, up from $3.1 million in the same period in 2024, resulting in a gross margin of 53.5% compared to 45.6% in Q1 2024 [17] - Total operating expenses decreased to $5.7 million in Q1 2025 from $6.0 million in Q1 2024, a reduction of 5% [18] - Cash burn improved to $749,000 in Q1 2025 from $1.55 million in the prior year [19] Business Line Data and Key Metrics Changes - The installed base of XTRAC devices in the U.S. is approximately 850, with a significant increase in recurring revenue per device [6][11] - The TheraClear X device installed base reached 160 units, up from 104 units at the end of Q1 2024, with revenue growing over 50% year-over-year in six of the last seven quarters [13] - The number of patients submitted for reimbursement for TheraClear X increased by 138% year-over-year, with pre-authorization rates exceeding 85% [14][29] Market Data and Key Metrics Changes - International business sales reached $2.5 million, up 8% year-over-year, with equipment sales up 13% and recurring treatments revenue up 27% [14] - The company is cautiously monitoring the potential negative impact of tariffs on international sales, particularly in Asian markets [15][41] Company Strategy and Development Direction - The company is executing a multifaceted turnaround strategy focused on increasing recurring revenue per device and optimizing device placements [5] - The Elevate360 consulting model is being expanded to improve patient conversion and device utilization in underperforming clinics [6][7] - The strategy includes removing underutilized devices to ensure capital efficiency and focusing on clinics that show potential for growth [9][54] Management's Comments on Operating Environment and Future Outlook - Management cautioned about potential impacts of tariffs on international business, although there was no immediate effect observed in Q1 2025 [20] - The company anticipates favorable outcomes from ongoing discussions regarding reimbursement coverage expansions [12] - Management expressed optimism about the traction gained from the turnaround strategy and the increase in demand for cost-effective treatments [14] Other Important Information - The company exited Q1 2025 with cash and cash equivalents totaling $7.8 million, including $1.3 million of restricted cash [20] - The average revenue per XTRAC device in the U.S. was approximately $22,000 in 2024, indicating potential for significant revenue growth with increased utilization [10] Q&A Session Summary Question: Can you discuss the TheraClear pipeline and marketplace learnings? - Management noted that the installed base is growing, with 160 devices deployed and a significant increase in patients submitted for reimbursement [24][25] Question: What are the utilization trends for TheraClear? - Management provided insights on the revenue breakeven points and the expected number of procedures per device, indicating a focus on increasing utilization [31] Question: What is the potential impact of tariffs on domestic business? - Management clarified that the domestic supply chain is minimally impacted by tariffs, but there are peripheral effects due to suppliers raising prices [41][42] Question: What is the focus for the rest of 2025 regarding the installed base? - Management indicated a dual focus on increasing utilization of the current installed base while also signing new clinics [46][54] Question: How many clinics could benefit from the Elevate360 program? - Management stated that they are currently implementing the program in about 100 accounts, with plans for further expansion [58][60]